The KNOP1 Knockout NCI-H1975 Polyclonal Cells represent a precisely engineered cellular model in which the KNOP1 gene has been functionally disrupted using CRISPR/Cas9 technology. This product is delivered as a polyclonal knockout cell population, comprising a heterogeneous mixture of individual NCI-H1975 cells that harbor diverse editing events at the target locus. The CRISPR/Cas9-mediated gene disruption establishes a loss-of-function model that enables investigation of KNOP1 ablation without the confounding influence of single-clone artifacts. This format yields a more holistic representation of knockout effects, enhancing the reliability and reproducibility of downstream experimental outcomes.
The parental NCI-H1975 cell line is a widely employed model of non-small cell lung cancer, originally established from a lung adenocarcinoma patient. It displays hallmark features of adenocarcinoma, including mutations in EGFR and TP53, and is extensively used to study oncogenic signaling, drug resistance mechanisms, and tumor biology. This host cell background provides a clinically relevant context for examining the impact of KNOP1 loss in a cancer-derived epithelial system.
KNOP1 encodes an essential subunit of the minor spliceosome, the ribonucleoprotein complex responsible for recognizing and excising the rare U12-type introns. The minor spliceosome is composed of specific small nuclear ribonucleoproteins, including U11 and U12 snRNPs, along with protein factors such as SNRNP25, SNRNP35, PHF5A, and SF3B1. KNOP1 functions downstream of U11 snRNP assembly and interacts directly with the U12 snRNP and the SNRNP25/35 complex to facilitate prespliceosome formation. Through this mechanism, KNOP1 mediates the splicing of U12-dependent introns found in genes encoding components of MAPK signaling pathways and DNA repair machinery. Loss of KNOP1 disrupts minor intron splicing, leading to aberrant expression of these downstream targets and altered cellular signaling. The minor spliceosome is itself subject to regulation by upstream transcriptional factors that modulate KNOP1 expression, although these regulators remain poorly defined.
In the NCI-H1975 adenocarcinoma model, ablation of KNOP1 serves as a powerful paradigm for dissecting the role of minor spliceosome function in lung cancer pathogenesis. Dysregulated splicing is a hallmark of malignancy, and growing evidence links vulnerabilities in minor spliceosome activity to tumor cell survival. By eliminating KNOP1, researchers can probe how impaired U12-type intron splicing influences proliferation, apoptosis, and therapeutic sensitivity in NSCLC. The polyclonal knockout population mitigates clonal biases, providing a more faithful assessment of gene function and facilitating the identification of robust splicing-dependent phenotypes.
This product is ideally suited for functional studies of the minor spliceosome and cancer-associated splicing vulnerabilities. Investigators can employ western blotting and RT-qPCR to validate knockout efficiency and monitor changes in target gene expression, while RNA-seq enables comprehensive profiling of splicing alterations and transcriptional responses. Co-immunoprecipitation assays can confirm interactions among minor spliceosome components, and cell viability or clonogenic assays are invaluable for assessing the impact of KNOP1 loss on tumorigenic potential and drug sensitivity. The polyclonal KO cells thus represent a versatile tool for mechanistic research, high-content screening, and drug target validation in non-small cell lung cancer. For further details and technical assistance, please contact Ascent Research.
